Who We Are
- Leadership Team
- Board of Directors
Our Platform
- Posters & Publications
Our Pipeline
- Inflammatory Diseases
Patients, Families & Physicians
Investors & Media

Careers
Contact Us

Skip to main content
Skip to footer

Discover how Evelo’s EDP1815 may prevent the progression of COVID-19. Learn More

Evelo

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

Home/Publications/Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

November 27, 2015 by

Footer

Terms of Use/Privacy Policy

© Evelo Biosciences, Inc.
EVELO is a registered U.S. trademark of Evelo Biosciences, Inc.

Follow Us LinkedIn